Zevra Therapeutics, Inc. (ZVRA) — Financial statements
Income statement, balance sheet, and cash flow for Zevra Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 106↑350.9% | 24↓14.0% | 27↑170.3% | 10↓64.5% | 29 | |
| Cost of Revenue | 16↑122.2% | 7↑151.9% | 3↑1226.6% | 0.22↓89.2% | 2 | |
| Gross Profit | 90↑455.7% | 16↓33.9% | 25↑146.7% | 10↓62.6% | 27 | |
| Operating Expenses | ||||||
| R&D Expenses | 13↓69.7% | 42↑5.8% | 40↑101.0% | 20↑94.9% | 10 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00↓100.0% | 15↑76.3% | 9 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↑100.0% | -0.31 | 0.00 | |
| SG&A Expenses | 78↑41.5% | 55↑56.4% | 35↑133.3% | 15↑72.8% | 9 | |
| Other Expenses | 4↓38.1% | 6↑904.5% | -0.78↓104.4% | 18 | 0.00 | |
| Operating Expenses | 94↓8.7% | 103↑39.2% | 74↑41.2% | 53↑178.4% | 19 | |
| Total Costs & Expenses | 111↑0.1% | 111↑43.5% | 77↑46.2% | 53↑152.0% | 21 | |
| Operating Results | ||||||
| Operating Income | -4↑95.1% | -87↓75.4% | -50↓16.5% | -43↓650.7% | 8 | |
| Depreciation & Amortization | 4↓36.5% | 6↑535.1% | 1↑6.6% | 0.94↑267.3% | 0.26 | |
| EBITDA | 99↑229.2% | -76↓75.5% | -44↓70.6% | -26↓223.6% | -8 | |
| EBIT | 95↑214.3% | -83↓85.8% | -45↓68.3% | -26↓225.0% | -8 | |
| Interest & Other Income | ||||||
| Net Interest Income | -1↑80.1% | -5↓270.3% | 3↑158.1% | 1↑1124.3% | -0.12 | |
| Interest Income | 7↑219.4% | 2↓52.1% | 5↑200.1% | 2↑479.7% | 0.26 | |
| Interest Expense | 8↑8.5% | 7↑389.7% | 2↑348.1% | 0.34↓10.9% | 0.38 | |
| Non-Operating Income | -99↓2246.7% | -4↑16.7% | -5↑68.6% | -16↓201.4% | 16 | |
| Other Income / Expenses | 91↑2998.0% | -3↓188.2% | 4↓77.4% | 16↑197.0% | -16 | |
| Income Before Tax | 87↑196.2% | -90↓95.7% | -46↓71.8% | -27↓214.6% | -9 | |
| Income Tax Expense | 3↓77.6% | 15 | 0.00↑100.0% | -0.03↓197.1% | 0.03 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 83↑178.9% | -106↓129.1% | -46↓72.0% | -27↓212.9% | -9 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 83↑178.9% | -106↓129.1% | -46↓72.0% | -27↓212.9% | -9 | |
| Bottom-Line Net Income | 78↑173.5% | -106↓129.1% | -46↓72.0% | -27↑57.4% | -63 | |
| EPS (Basic) | 1.40↑161.4% | -2.28↓75.4% | -1.30↓66.7% | -0.78↑63.0% | -2.11 | |
| EPS (Diluted) | 1.35↑159.2% | -2.28↓75.4% | -1.30↓66.7% | -0.78↑63.0% | -2.11 | |
| Weighted Average Shares | 55↑19.6% | 46↑30.5% | 35↑2.8% | 34↑15.9% | 30 | |
| Weighted Average Diluted Shares | 57↑23.8% | 46↑30.5% | 35↑2.8% | 34↑15.9% | 30 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.